APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Beijing Yuanxin (北京圆心) Pre-IPO - Growing at the Expense of Margins

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Beijing Yuanxin Technology Group Co Ltd / Equity Capital Markets

Beijing Yuanxin Technology Group Co Ltd (1865453D CH)

<p><a href="https://www.smartkarma.com/entities/beijing-yuanxin-technology-group-co-ltd" target="_blank" data-smartkarma-citation="entities:34685:1" rel="noopener">Beijing Yuanxin Technology Group Co Ltd (1865453D CH)</a> is looking to raise US$500m in its upcoming Hong Kong IPO. The deal will be run by Goldman Sachs and CITIC Securities.</p><p>Beijing Yuanxin Technology Group is a pharmaceutical firm operating under the Miaoshu Physician and Yuanxin Pharmacy brands. As per Frost &amp; Sullivan (F&amp;S), the firm is the No. 1 integrated healthcare fulfilment platform in China focusing on prescription drugs. The firm also operates its brick-and-mortar pharmacies under the Yuanxin Pharmacy brand, and as of 8M21, had 251 pharmacies over 30 provinces in China.</p>

Beijing Yuanxin Technology Group Co Ltd (1865453D CH) is looking to raise US$500m in its upcoming Hong Kong IPO. The deal will be run by Goldman Sachs and CITIC Securities.Beijing Yuanxin Technology Group is a pharmaceutical firm operating under the Miaoshu Physician and Yuanxin Pharmacy brands. As per Frost &amp; Sullivan (F&amp;S), the firm is the No. 1 integrated healthcare fulfilment platform in China focusing on prescription drugs. The firm also operates its brick-and-mortar pharmacies under the Yuanxin Pharmacy brand, and as of 8M21, had 251 pharmacies over 30 provinces in China.

Shukun (Beijing) Technology (1702626D CH)

Beijing Yuanxin Technology Group Pre-IPO Tearsheet